Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Jill Roberts Center for Inflammatory Bowel Disease
Explore this Website
Home
About Us
Toggle About Us menu options
Clinical Staff
Research Staff
Contact Us
Newsworthy
Toggle Newsworthy menu options
News and Announcements
Patient Care
Toggle Patient Care menu options
Clinical Services
FAQs
For Your Visit
COVID-19 Information
Nutrition Science
Toggle Nutrition Science menu options
Nutrition FAQs
Food Intolerances
News in IBD Nutrition
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Clinical Trials
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Newsworthy
Patient Care
Nutrition Science
Research and Clinical Trials
Home
Publications
Publications
Clinical Trials
Publications
Publications
Found 238 results
Author
Title
[
Type
]
Year
Filters:
First Letter Of Last Name
is
S
[Clear All Filters]
Journal Article
Shen T-CDavid
,
Lebwohl B
,
Verma H
,
Kumta N
,
Tennyson C
,
Lewis S
,
Scherl E
,
Swaminath A
,
Capiak KM
,
DiGiacomo D
et al.
. 2012.
Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease.
.
J Clin Neuromuscul Dis. 13(3):137-45.
Shen T-CDavid
,
Lebwohl B
,
Verma H
,
Kumta N
,
Tennyson C
,
Lewis S
,
Scherl E
,
Swaminath A
,
Capiak KM
,
DiGiacomo D
et al.
. 2012.
Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease.
.
J Clin Neuromuscul Dis. 13(3):137-45.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Poppers DM
,
Scherl EJ
. 2008.
Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care.
.
Inflamm Bowel Dis. 14(1):106-13.
Lewis JD
,
Sandler RS
,
Brotherton C
,
Brensinger C
,
Li H
,
Kappelman MD
,
Daniel SG
,
Bittinger K
,
Albenberg L
,
Valentine JF
et al.
. 2021.
A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.
.
Gastroenterology. 161(3):837-852.e9.
Lewis JD
,
Sandler RS
,
Brotherton C
,
Brensinger C
,
Li H
,
Kappelman MD
,
Daniel SG
,
Bittinger K
,
Albenberg L
,
Valentine JF
et al.
. 2021.
A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.
.
Gastroenterology. 161(3):837-852.e9.
Lewis JD
,
Sandler RS
,
Brotherton C
,
Brensinger C
,
Li H
,
Kappelman MD
,
Daniel SG
,
Bittinger K
,
Albenberg L
,
Valentine JF
et al.
. 2021.
A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.
.
Gastroenterology. 161(3):837-852.e9.
Lewis JD
,
Sandler RS
,
Brotherton C
,
Brensinger C
,
Li H
,
Kappelman MD
,
Daniel SG
,
Bittinger K
,
Albenberg L
,
Valentine JF
et al.
. 2021.
A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.
.
Gastroenterology. 161(3):837-852.e9.
Lewis JD
,
Sandler RS
,
Brotherton C
,
Brensinger C
,
Li H
,
Kappelman MD
,
Daniel SG
,
Bittinger K
,
Albenberg L
,
Valentine JF
et al.
. 2021.
A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.
.
Gastroenterology. 161(3):837-852.e9.
Lewis JD
,
Sandler RS
,
Brotherton C
,
Brensinger C
,
Li H
,
Kappelman MD
,
Daniel SG
,
Bittinger K
,
Albenberg L
,
Valentine JF
et al.
. 2021.
A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.
.
Gastroenterology. 161(3):837-852.e9.
Sandborn WJ
,
Feagan BG
,
Fedorak RN
,
Scherl E
,
Fleisher MR
,
Katz S
,
Johanns J
,
Blank M
,
Rutgeerts P
. 2008.
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
.
Gastroenterology. 135(4):1130-41.
Sandborn WJ
,
Feagan BG
,
Fedorak RN
,
Scherl E
,
Fleisher MR
,
Katz S
,
Johanns J
,
Blank M
,
Rutgeerts P
. 2008.
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
.
Gastroenterology. 135(4):1130-41.
Longman RS
,
Moreira RK
,
Littman DR
,
Green PHR
,
Sethi A
. 2012.
A rare intestinal infection with systemic effects.
.
Gastroenterol Hepatol (N Y). 8(1):60-3.
J Blander M
,
Longman RS
,
Iliev ID
,
Sonnenberg GF
,
Artis D
. 2017.
Regulation of inflammation by microbiota interactions with the host.
.
Nat Immunol. 18(8):851-860.
Scherl EJ
,
Kumar S
,
Warren RU
. 2010.
Review of the safety and efficacy of ustekinumab.
.
Therap Adv Gastroenterol. 3(5):321-8.
Dogan B
,
Fu J
,
Zhang S
,
Scherl EJ
,
Simpson KW
. 2018.
Rifaximin decreases virulence of Crohn's disease-associated Escherichia coli and epithelial inflammatory responses.
.
J Antibiot (Tokyo). 71(5):485-494.
Dogan B
,
Fu J
,
Zhang S
,
Scherl EJ
,
Simpson KW
. 2018.
Rifaximin decreases virulence of Crohn's disease-associated Escherichia coli and epithelial inflammatory responses.
.
J Antibiot (Tokyo). 71(5):485-494.
« first
‹ previous
…
2
3
4
5
6
7
(current)
8
9
10
next ›
last »